ストックスクリーナーアプリを入手
1.38
2.13%
-0.03
アフターアワーズ：
1.39
0.01
+0.72%
前日終値:
$1.41
開ける：
$1.41
24時間の取引高:
12.72M
Relative Volume:
1.45
時価総額：
$467.16M
収益：
$4.41M
当期純損益:
$-67.85M
株価収益率:
-6.1116
EPS:
-0.2258
ネットキャッシュフロー:
$-57.15M
1週間 パフォーマンス:
+2.99%
1か月 パフォーマンス:
-17.86%
6か月 パフォーマンス:
+11.29%
1年 パフォーマンス:
+65.43%
1日の値動き範囲:
$1.37
$1.415
1週間の範囲:
$1.34
$1.43
52週間の値動き範囲:
$0.80
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.38 | 477.32M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Canaccord Genuity | Buy |
| 2026-03-11 | 開始されました | Oppenheimer | Outperform |
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen stock dips as Q1 losses widen - MSN
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity - Moomoo
OCGN Maintained by Canaccord Genuity -- Price Target Lowered to $11 - GuruFocus
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
Ocugen Is Maintained at Buy by Canaccord Genuity - Moomoo
Canaccord lowers Ocugen stock price target to $11 on model update By Investing.com - Investing.com South Africa
Canaccord lowers Ocugen stock price target to $11 on model update - Investing.com
CCORF Maintains Ocugen(OCGN.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
FTSE Russell Index Reconstitution Sees Major Changes with Ocugen (OCGN) Joining - GuruFocus
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Ocugen (OCGN) Set for Inclusion in Russell 3000 Index Rebalancin - GuruFocus
OCGN Stock Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc stock (US67577C1053): FDA feedback keeps retinitis pigmentosa trial on track - AD HOC NEWS
Stock Quote & Chart - Ocugen, Inc.
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen closes $130 million convertible notes offering - Investing.com UK
Gene therapy pipeline accelerates as Ocugen, Inc. targets approvals for RP and Stargardt disease - Traders Union
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout
Ocugen Raises $130 Million Through Convertible Notes Offering - TipRanks
Ocugen Announces Interim Chief Medical Officer Appointment Transition - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Ocugen closes $130 million convertible notes offering By Investing.com - Investing.com Australia
Ocugen Reports Positive GA Trial Data, Extends Cash Runway - MyChesCo
Ocugen (NASDAQ: OCGN) shifts CMO duties to interim leader - Stock Titan
Ocugen (NASDAQ: OCGN) closes $130M 6.75% convertible notes due 2034 - Stock Titan
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
Ocugen to Participate in Upcoming May Scientific and Investor Conferences - Sahm
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Ocugen’s Convertible Cash and Reverse Split Vote Set the Table for a Triple-Data Summer - AD HOC NEWS
Ocugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 Conferences - Quiver Quantitative
Ocugen brings blindness gene therapy to two May events in 2026 - Stock Titan
Ocugen (OCGN) Reports Q1 EPS - Insider Monkey
Ocugen’s Clinical Calendar Packs a Punch in Q3 as Analysts Stay Bullish on Gene Therapy Pipeline - AD HOC NEWS
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop - AD HOC NEWS
Ocugen, Inc. advances automation in quantitative autofluorescence for geographic atrophy at ARVO2026 - Traders Union
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
1.35%
大文字化:
|
ボリューム (24 時間):